Incyte Outlines Post-Jakafi Growth Strategy at Barclays Conference

Biotech company highlights new launches, mid-stage pipeline to sustain growth after loss of Jakafi exclusivity.

Mar. 21, 2026 at 9:07am

Got story updates? Submit your updates here. ›

Incyte executives outlined the company's near-term launch priorities and mid-stage pipeline plans during a presentation at the Barclays conference, emphasizing a strategy to sustain growth ahead of the loss of exclusivity for its flagship product Jakafi in 2029. The company discussed plans for four product launches over the next 12-18 months, as well as progress on its myeloproliferative neoplasms (MPNs) program, immunology franchise, and solid tumor oncology pipeline.

Why it matters

Jakafi has been Incyte's primary revenue driver since its approval in 2011, so the company's ability to successfully launch new products and advance its pipeline is crucial to sustaining growth after the loss of Jakafi exclusivity. The company's diversification strategy across hematology, solid tumors, and immunology aims to reduce its reliance on a single blockbuster product.

The details

Incyte CEO Bill Meury outlined the company's three therapeutic focus areas: hematology, solid tumor oncology, and immunology. In hematology, the company is advancing INCB0989, a monoclonal antibody targeting mutant calreticulin (mCALR), in myelofibrosis (MF) and essential thrombocythemia (ET). Incyte plans to start phase III studies in ET this year and MF later in 2023 or 2024. The company also discussed its JAK2 V617F inhibitor INCB160058 and plans to submit its CD19-targeted therapy Monjuvi for frontline diffuse large B-cell lymphoma (DLBCL) in the first half of 2026. In immunology, Incyte is focused on the oral JAK inhibitor povorcitinib in prurigo nodularis, hidradenitis suppurativa, and vitiligo. On the solid tumor side, the company highlighted its TGFβR2xPD-1 bispecific program in microsatellite-stable colorectal cancer and a KRAS G12D inhibitor in pancreatic cancer.

  • Incyte expects to submit povorcitinib for approval "at least by the end of 2026, early 2027".
  • Incyte plans to submit Monjuvi for frontline DLBCL in the first half of 2026, with a possible approval "at the end of 2026, early 2027".
  • Incyte expects to provide a data update on its TGFβR2xPD-1 bispecific program in MSS colorectal cancer around mid-2026.
  • Incyte expects to provide an update on its KRAS G12D inhibitor combination data in pancreatic cancer in the second half of 2026.

The players

Incyte

A Wilmington, Delaware-based biopharmaceutical company focused on the discovery, development and commercialization of novel therapies in oncology and inflammation.

Bill Meury

Chief Executive Officer of Incyte.

Pablo Cagnoni

Head of R&D at Incyte.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident

“Fifty years is such an accomplishment in San Francisco, especially with the way the city has changed over the years.”

— Gordon Edgar, grocery employee

The takeaway

Incyte's diversification strategy across hematology, solid tumors, and immunology aims to reduce its reliance on Jakafi and build a more sustainable business model ahead of the loss of exclusivity for its flagship product. The company's pipeline progress, particularly in areas like myelofibrosis and colorectal cancer, will be closely watched as it works to establish new growth drivers.